Skip to main content

Table 1 Demographic, clinical and echocardiographic characteristics according to tertiles of IGF BP 7

From: IGFBP7 and GDF-15, but not P1NP, are associated with cardiac alterations and 10-year outcome in an elderly community-based study

 

Total

IGFBP7 (ng/mL)

p

Tertile 1

Tertile 2

Tertile 3

N = 1913

N = 631

N = 632

N = 650

IGFBP7

Median [IQR]

165.5 [150.7–183.6]

145.4 [138.0–150.6]

165.1 [160.2–170.5]

193.9 [182.8–210.3]

–

Range

92.4–617.8

92.4–155.2

155.3–175.8

175.9–617.8

Age, years

Mean ± SD

72.7 ± 5.0

70.8 ± 4.1

72.2 ± 4.5

75.2 ± 5.2

3.4 × 10−61

Females

N (%)

925 (48.4)

366 (58.0)

309 (48.9)

250 (38.5)

2.2 × 10−11

BMI, kg/m2

Mean ± SD

26.5 ± 4.2

26.2 ± 4.0

26.7 ± 4.1

26.5 ± 4.3

0.084

BSA, m2

Mean ± SD

1.80 ± 0.19

1.77 ± 0.18

1.82 ± 0.20

1.83 ± 0.18

6.4 × 10−9

Serum creatinine, mg/dL−1

Mean ± SD

0.96 ± 0.26

0.85 ± 0.17

0.93 ± 0.19

1.10 ± 0.33

1.6 × 10−71

eGFR, mL/min/1.73m2

Mean ± SD

69.6 ± 21.1

75.6 ± 19.8

72.2 ± 21.5

61.0 ± 19.0

1.4 × 10−38

CKD (eGFR < 60)

N (%)

632 (33.4%)

123 (19.6%)

176 (27.9%)

333 (52.2%)

3.6 × 10−36

Clinical history

Hypertension

N (%)

1132 (59.2)

357 (56.6)

375 (59.3)

400 (61.5)

0.195

Diabetes mellitus

N (%)

313 (16.5)

91 (14.6)

91 (14.4)

131 (20.2)

0.006

Smoking

N (%)

252 (13.2)

88 (13.9)

83 (13.2)

81 (12.5)

4.1 × 10−7

Alcohol use

N (%)

1128 (59.0)

367 (58.2)

382 (60.5)

379 (58.3)

0.628

Dyslipidemia

N (%)

828 (44.3)

302 (49.2)

268 (43.1)

258 (40.8)

0.009

Angina pectoris

N (%)

121 (6.3)

41 (6.5)

41 (6.5)

39 (6.0)

0.916

Myocardial infarction

N (%)

116 (6.1)

34 (5.4)

28 (4.5)

54 (8.4)

0.010

Atrial fibrillation

N (%)

132 (6.9)

28 (4.4)

35 (5.5)

69 (10.6)

1.9 × 10−5

Heart failure

N (%)

114 (6.3)

18 (3.0)

35 (5.7)

61 (10.0)

2.0 × 10−6

AHA/ACC class

Normal

N (%)

242 (12.7)

104 (16.5)

85 (13.4)

53 (8.2)

1.8 × 10−7

A

N (%)

444 (23.2)

148 (23.5)

139 (22.0)

157 (24.2)

B

N (%)

1113 (58.2)

361 (57.2)

373 (59.0)

379 (58.3)

C

N (%)

114 (6.0)

18 (2.9)

35 (5.5)

61 (9.4)

COPD

N (%)

171 (8.9)

48 (7.6)

56 (8.9)

67 (10.3)

0.237

Circulating biomarkers

GDF-15, pg/mL

Median [IQR]

1468 [1168–1984]

1250 [1021–1527]

1405 [1168–1761]

1915 [1445–2603]

3.7 × 10−82

P1NP, ng/mL

Median [IQR]

35.2 [26.3–46.0]

32.6 [24.5–42.6]

34.9 [26.0–45.5]

37.2 [27.5–51.3]

2.9 × 10−7

hs cTnT, ng/L

Median [IQR]

5.5 [3.0–9.5]

3.5 [3.0–6.3]

5.0 [3.0–8.2]

8.1 [4.9–13.7]

5.7 × 10−58

NT-proBNP, ng/L

Median [IQR]

92 [47–186]

63 [36–123]

81 [45–151]

142 [69–293]

8.9 × 10−42

Echocardiography

LVEF, %

(N = 1858)

Mean ± SD

66.3 ± 7.2

66.9 ± 6.2

66.7 ± 6.9

65.2 ± 8.3

8.1 × 10−5

LAA-, cm2 (N = 1332)

Mean ± SD

11.1 ± 4.1

10.4 ± 3.6

10.9 ± 3.5

11.9 ± 4.9

8.1 × 10−7

LV mass / BSA, g/m2 (N = 1489)

Mean ± SD

91.9 ± 23.3

87.4 ± 19.5

92.7 ± 23.8

95.8 ± 25.4

2.5 × 10−8

LVH

(N = 1853)

N (%)

373 (24.4)

99 (18.9)

127 (25.1)

147 (29.3)

4.9 × 10−4

MFS reduced

(N = 1470)

N (%)

448 (31.9)

136 (28.6)

137 (29.6)

175 (37.5)

0.006

E/e’ > 8

(N = 1801)

N (%)

765 (44.4)

216 (38.0)

261 (45.5)

288 (49.7)

3.2 × 10−4

Enlarged LA-area (N = 1332)

N (%)

41 (3.2)

7 (1.7)

8 (1.8)

26 (6.2)

1.2 × 10−4

Outcomes (N = 1715)

All-cause mortality

N (%)

491 (30.0)

104 (19.7)

130 (23.8)

257 (45.7)

4.9 × 10−23

CV mortality

N (%)

115 (6.0)

19 (3.0)

24 (3.8)

72 (11.1)

1.6 × 10−10

Hospitalization

N (%)

1297 (79.3)

392 (74.4)

439 (80.3)

466 (82.9)

0.002

CV hospitalization

N (%)

583 (35.6)

143 (27.1)

210 (38.4)

230 (40.9)

3.0 × 10−6

HF hospitalization

N (%)

168 (10.3)

25 (4.7)

50 (9.1)

93 (16.3)

6.7 × 10−10

  1. BMI, body mass index; BSA, body surface area; CKD, chronic kidney disease defined as eGFR < 60; CV, cardiovascular; COPD, chronic obstructive pulmonary disease; E/e ‘ > 8 vs <  = 8; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; hs cTnT, high sensitivity cardiac troponin T; IGFBP7, insulin grow factor binding protein; LAA, left atrial area, enlarged if > 20 cm2; LVEF, left ventricular ejection fraction; LVH: Left ventricular hypertrophy defined as LV mass/BSA > 95 g/m2 for women and > 115 g/m2 for men; MFS, midwall circumference fraction shortening, reduced if MFS < 15%; NTproBNP, N-terminal probrain natriuretic peptide; P1NP, amino-terminal propeptide of type I procollagen. Continuous data is presented either as mean ± SD or median [IQR]
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us